Table 1 General characteristics of patients
From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
No adjuvant therapy (n = 59) | Platinum-based chemotherapy (n = 60) | p value | |
|---|---|---|---|
Age (years) | 64.14 ± 12.75 | 59.80 ± 9.70 | 0.027 |
Male | 36 (61.0%) | 37 (61.7%) | 0.546 |
FEV1 (liters) | 90.10 ± 25.99 | 97.91 ± 25.40 | 0.1 |
Comorbidity | 38 (64.4%) | 33 (55.0%) | 0.352 |
Type of operation | 0.489 | ||
Lobectomy | 54 (91.5%) | 56 (93.3%) | |
Pneumonectomy | 5 (8.5%) | 4 (6.7%) | |
Dissected lymph nodes | 22.88 ± 9.21 | 28.08 ± 13.08 | 0.017 |
Tumor size (mm) | 28.35 ± 9.74 | 33.80 ± 9.82 | 0.003 |
Pathology | 0.295 | ||
Adenocarcinoma | 27 (45.8%) | 36 (60.0%) | |
Squamous cell carcinoma | 18 (30.5%) | 14 (23.3%) | |
Others | 14 (23.7%) | 10 (16.7%) | |
Differentiation | 0.306 | ||
Well | 17 (28.8%) | 12 (20.0%) | |
Moderate to poor | 37 (62.7%) | 39 (65.0%) | |
Not defined | 5 (8.5%) | 9 (15.0%) | |
Lymphovascular invasion | 8 (13.6%) | 11 (18.3%) | 0.323 |
Pleural invasion | 0.428 | ||
pl0 | 34 (57.6%) | 28 (46.7%) | |
pl1 | 15 (25.4%) | 17 (28.3%) | |
pl2 | 10 (16.9%) | 15 (25.0%) | |
Performance status (ECOG) | 0.004 | ||
0 | 36 (61.0%) | 52 (86.7%) | |
1 | 20 (33.9%) | 8 (13.3%) | |
2 | 3 (5.1%) | 0 |